Case number 1:18-cv-00525
iCeutica Pty Ltd. et al v. Teva Pharmaceuticals USA, Inc. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 8, 2020 | 1 | Complaint (27) |
| May 16, 2018 | 10 | Redacted Document (3) Docket Text: REDACTED VERSION of [9] Stipulation of Dismissal by Iroko Pharmaceuticals, LLC, iCeutica Pty Ltd.. (Winter, Christopher) |
| May 9, 2018 | N/A | SO ORDERED (0) Docket Text: SO ORDERED D.I. [9] Stipulation of Dismissal filed by iCeutica Pty Ltd., Iroko Pharmaceuticals, LLC. Ordered by Judge Christopher J. Burke on 5/9/2018. (dlb) |
| May 9, 2018 | N/A | Terminated Case (0) Docket Text: CASE CLOSED (dlb) |
| Apr 27, 2018 | N/A | SO ORDERED (0) |
| Apr 27, 2018 | 8 | Stipulation to EXTEND Time (2) Docket Text: STIPULATION TO EXTEND TIME to Respond to the Complaint to May 14, 2018 - filed by Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals USA, Inc.. (Shaw, John) |
| Apr 11, 2018 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Vacant Judgeship (2017). Please include initials of VAC after the case number on all documents filed. (rjb) |
| Apr 11, 2018 | N/A | Case Referred to Magistrate Judge (0) Docket Text: CASE REFERRED to Magistrate Judge Christopher J. Burke. (This matter has been assigned to the Vacant Judgeship and referred to a Magistrate Judge for handling through case-dispositive motions. The Magistrate Judge has full authority permitted by law to manage this matter, including entering schedules through trial, deciding non-dispositive matters and making recommendations as to the resolution of dispositive matters. Litigants and counsel are reminded that they have the option of consenting to the Magistrate Judge to handle the case in full, including trial, or consenting to having a particular motion resolved by the Magistrate Judge.) (rjb) |
| Apr 11, 2018 | N/A | Remark (0) Docket Text: REMARK: If the parties jointly consent to have a Magistrate Judge conduct all proceedings in this case, including trial, then when Judge Burke enters a case schedule he will enter the respective pre-trial conference and trial dates onto his calendar and will honor them. Otherwise, in accordance with the District Court's procedures for "Assignment of Cases to Visiting Judges" (issued on May 26, 2017 and available on the District Court's website), then upon the filing of a case-dispositive motion (e.g., a motion to dismiss, a motion for judgment on the pleadings, a motion for summary judgment, or initiation of the claim construction process in a patent case), VAC cases will be considered ready for reassignment to a visiting District Judge. Whether the pre-trial conference and trial dates will stand after reassignment will depend on the availability of those dates on the visiting District Judge's calendar. (dlb) |
| Apr 11, 2018 | 7 | Summons Returned Executed (2) Docket Text: SUMMONS Returned Executed by iCeutica Pty Ltd., Iroko Pharmaceuticals, LLC. Teva Pharmaceuticals USA, Inc. served on 4/9/2018, answer due 4/30/2018. (Winter, Christopher) |
| Apr 9, 2018 | N/A | No Summons Issued (0) Docket Text: No Summons Issued. (nmfn) |
| Apr 9, 2018 | N/A | Summons Issued (0) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Teva Pharmaceuticals USA, Inc. on 4/9/2018. (nmfn) |
| Apr 6, 2018 | 1 | Exhibit A (17) |
| Apr 6, 2018 | 1 | Exhibit B (17) |
| Apr 6, 2018 | 1 | Exhibit C (18) |
| Apr 6, 2018 | 1 | Civil Cover Sheet (1) |
| Apr 6, 2018 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (nmfn) |
| Apr 6, 2018 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 2/28/2018. Date of Expiration of Patent: 3/31/2033.Thirty Month Stay Deadline: 8/28/2020. (nmfn) |
| Apr 6, 2018 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,526,734; 9,649,318; 9,808,468. (nmfn) |
| Apr 6, 2018 | 5 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent iCeutica Inc. for iCeutica Pty Ltd. filed by iCeutica Pty Ltd. (nmfn) |
| Apr 6, 2018 | 6 | Disclosure Statement (1) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Iroko Intermediate Holdings, Inc. for Iroko Pharmaceuticals, LLC filed by Iroko Pharmaceuticals, LLC. (nmfn) |
| Apr 6, 2018 | 1 | Main Document (27) Docket Text: COMPLAINT FOR PATENT INFRINGEMENT filed against Teva Pharmaceutical Industries Limited, Teva Pharmaceuticals USA, Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 0311-2356852.) - filed by iCeutica Pty Ltd., Iroko Pharmaceuticals, LLC. (Attachments: # (1) Exhibit A, # (2) Exhibit B, # (3) Exhibit C, # (4) Civil Cover Sheet)(nmfn) (Attachment 4 replaced on 4/9/2018) (nmg). |
| Apr 6, 2018 | 1 | Complaint* (1) |
